@article{JGO27857,
author = {Ravi Shridhar and Caitlin Takahashi and Jamie Huston and Kenneth L. Meredith},
title = {Neoadjuvant therapy and pancreatic cancer: a national cancer database analysis},
journal = {Journal of Gastrointestinal Oncology},
volume = {10},
number = {4},
year = {2019},
keywords = {},
abstract = {Background: We sought to examine the impact of neoadjuvant chemotherapy (NCT), single agent or multiagent chemotherapy, and neoadjuvant chemoradiation (NCRT) on survival in pancreatic cancer.
Methods: Utilizing the National Cancer Database, we identified patients who underwent pancreatic resection for adenocarcinoma (2006 to 2013). Overall survival (OS) analysis was performed using the Kaplan-Meier method. Multivariable cox proportional hazard models (MVA) and propensity score matching (PSM) were developed to identify predictors of survival. For upfront surgery (UFS), OS was limited to receipt of adjuvant treatment.
Results: We identified 26,563 patients who underwent pancreatic resection: UFS =23,877, NCRT =1,482, and NCT =1,204. Multiagent chemotherapy was utilized in 77% of NCT and 42% of NCRT. There was improved R0 resections associated with neoadjuvant therapy compared to UFS, however, there was no difference between NCT and NCRT. In addition, the was improved R0 with MA-NCT (P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/27857}
}